Journal of Immunological Techniques in Infectious Diseases (JIDIT) is a scholarly peer-reviewed academic journal that encourages rigorous research that makes a significant contribution in advancing knowledge for immunological application in the treatment of various infectious diseases. JIDIT includes all major themes pertaining to Immunity, Immunization techniques, Vaccination, Epidemology and treatment of infectious diseases.
Scope of the Journal includes:
Epidemology & Pathogenesis of diseases
Diagnostic Techniques - Advancements
Immunolgy & Microbiology
Infectious Diseases & Immune responses
Vaccination and Development of Vaccines
Clinical & Experimental Immunology
Journal of Immunological Techniques in Infectious Diseasesis a subscription based scientific Journal that provides a range of options to individuals and university libraries to purchase our articles and also permits unlimited Internet Access to complete Journal content. However, JIDIT has recently started following Hybrid Model of publication of articles. Under hybrid model, journal is giving option to authors to choose their mode of publishing; either Open Access (making individual articles freely available online) or Subscription (article access restricted to journal subscribers).
JIDIT accepts wide range of articles including research, review, short communication, case report, rapid communication, letter to the editor, conference proceedings etc. The journal has a sound Editorial Board of experts in their fields. Articles submitted by authors are evaluated by Editors and a group of peer review experts in the field to ensure that the accepted and published articles are of high quality, reflect solid scholarship in their fields, and that the information they contain is accurate, reliable and beneficial to the scientific community. JIDIT uses Editorial Manager System for quality review process. Editorial Manager is an online manuscript submission, review and tracking systems. Authors can submit and track the progress of their articles through the system.
*Unofficial 2014 Impact Factor was established by dividing the number of articles published in 2012 and 2013 with the number of times they are cited in 2014 based on Google search and the Scholar Citation Index database. If ‘X’ is the total number of articles published in 2012 and 2013, and ‘Y’ is the number of times these articles were cited in indexed journals during 2014 than, impact factor = Y/X
Syphilis and leprosy have cutaneous manifestations with great lesional polymorphism with subsequent difficult differential diagnosis. Both have additional tests that, in certain situations, are inconclusive, making it difficult to confirm the clinical diagnosis. In medical literature there are several clinical cases reported in which patients with syphilis were erroneously diagnosed and treated as having leprosy. Physicians need to maintain a high index of suspicion for the diagnosis of syphilis.
Late-Onset Prosthetic Valve Fungal Endocarditis due to Candida albicans: A Case Report and Review of Literature from India
The incidence of prosthetic valve endocarditis (PVE) is 1-4%. Fungal endocarditis (FE) is an uncommon complication of valve replacement surgery. The incidence of PVE is highest within the first 12 months following surgery. We report here a fatal case of late-onset fungal endocarditis after 15 years of mitral valve replacement for which administration of amphotericin B is crucial for survival of patients.
Prospect of CD52 Targeted Alemtuzumab in Treatment of CNS Demyelination in Multiple Sclerosis
The choice of humanized monoclonal antibody is a novel therapeutic approach for autoimmune relapsing remitting multiple sclerosis (RRMS). In addition to anti-alpha-4 integr in monoclonal antibody Natalizumab, introduction of CAMPATH-1 (Alemtuzumab) is a fairly new approach in MS research and clinical trials. The uniqueness of this monoclonal antibodyis that it depletes CD52 marker expressing circulatory T and B cells including monocytes and dendritic cells. However, it has no impact on progenitor cells. Thus, the use of Alemtuzumab has gained importance in delaying rejection in allograft during transplantation.